David M. Kaufman
<p><span style="font-family: Arial;">David Myland Kaufman, Professor of Neurology and Psychiatry and Behavioral Sciences, was graduated from the medical school of the University of Chicago and completed training in internal medicine and then neurology at Montefiore Medical Center / Albert Einstein College of Medicine (AECOM) hospitals. During his residency, Dr. Kaufman originated the nation-wide course, which he still directs, Clinical Neurology for Psychiatrists. More than 25,500 psychiatry residents and attendings have attended the course, which has served as the basis for his classic textbook, <em>Clinical Neurology for Psychiatrists</em>, (Elsevier) currently in its eighth edition and available in Italian, Japanese, and Spanish translations. He is also a co-editor of <em>Child and Adolescent Neurology for Psychiatrists</em> (Lippincott).</span></p>
<p><span style="font-family: Arial;">Dr. Kaufman has also been a visiting professor at Ben Gurion University, Yale University, Pritzger / University of Chicago, and other American medical schools, and U.S. Naval Medical Centers, as well as a frequent lecturer at AECOM. He is a member of medical school's Leo M. Davidoff Society for excellence in teaching. </span></p>
<p><span style="font-family: Arial;">In addition to his educational role at AECOM hospitals, Dr. Kaufman in partnership with Dr. Michael Swerdlow founded the quintessential neurology faculty practice K&S at Montefiore Hospital. K&S is the largest and longest surviving faculty practice in the institution. Drs. Kaufman and Swerdlow also give neurology consultation and attending rounds and supervise neurology clinics at Montefiore. In the clinics and faculty practice, Dr. Kaufman concentrates on the neurologic aspects of psychiatric illness and movement disorders. He works closely with the psychiatrists and, for botulinum treatment of certain dystonias, the neuromuscular group. Dr. Kaufman is the 2007 recipient of Montefiore's Staff and Alumni award for outstanding service.</span></p>
In addition to his educational role at AECOM and its hospitals, Dr. Kaufman in partnership with Dr. Michael Swerdlow founded the quintessential neurology faculty practice K&S at Montefiore Hospital. K&S is the largest and longest-surviving faculty practice in the institution. Drs. Kaufman and Swerdlow also give neurology consultations and attend rounds and supervise neurology clinics at Montefiore. In the clinics and faculty practice, Dr. Kaufman concentrates on the neurologic aspects of psychiatric illness and movement disorders. He works closely with psychiatrists and, for botulinum treatment of certain dystonia, the neuromuscular group.
From his research interests, Dr. Kaufman has published clinical studies of central nervous system infections, heroin overdose-induced pulmonary edema, Covid’s effect on Parkinson's disease patients, and other topics. He concentrates on teaching medical students in their neuroscience courses, psychiatry and neurology residents, and psychiatrists preparing for their Board examinations.
<p>Kaufman DM, Geyer HL, Milstein MM: "Kaufman's Clinical Neurology for Psychiatrists," Elsevier, 8th Edition, 2017</p>
<p>Kaufman DM, Smuckler DJ: Neurologic Disease (in) Blumenfeld M, Strain JJ, "Psychosomatics," Lippincott Williams & Wilkins, 2006</p>
<p>David Kaufman, MD, an attending physician and Professor of Neurology and of Psychiatry and Behavioral Sciences at Montefiore Einstein, concentrates on the neurologic aspects of psychiatric illness and movement disorders. He provides neurology consultations for in-patients and out-patients, serves as the attending on consultation and ward rounds, and supervises neurology clinics at Montefiore Einstein. He works closely with psychiatrists and, for botulinum treatment of certain dystopias, the neuromuscular group.</p><p>After earning his Bachelor of Arts from the University of Rochester in 1964, Dr. Kaufman earned his Doctor of Medicine degree from the University of Chicago School of Medicine in 1968. He pursued his postdoctoral training at Montefiore, completing his internal medicine internship and residency in 1971. In 1975, he completed the four-year neurology residency at Albert Einstein College of Medicine hospitals. He has been a steadfast member of Montefiore and Einstein communities ever since.</p><p>From his research interests, Dr. Kaufman has published clinical studies of central nervous system infections, heroin overdose-induced pulmonary edema, COVID’s effect on Parkinson disease patients, and other topics. He has been a member of editorial boards for Internal Medicine Bulletin and Medical Meetings: Pearls & Perspectives, and a consultant and reviewer for numerous medical journals. He teaches medical students in their neuroscience course, psychiatry and neurology residents, and psychiatrists preparing for their Board examinations. He has been a Visiting Professor at Ben Gurion University, Yale University, Pritzker/University of Chicago, and other American medical schools, and at U.S. Naval Medical Centers, as well as a frequent lecturer at the Albert Einstein College of Medicine.</p><p>Dr. Kaufman innovated the long-standing, annual, national course, Clinical Neurology and Psychiatry for Psychiatrists, developed a noteworthy neuropsychiatry seminar and authored the book, <em>Kaufman’s Clinical Neurology for Psychiatrists</em>, now in its 9th edition.</p><p>Dr. Kaufman is board certified in Internal Medicine, and Psychiatry and Neurology. He is a fellow of the American Academy of Neurology and the American College of Physicians. He is also a member of the American Neuropsychiatric Association and the Movement Disorder Society. A devoted educator, Dr. Kaufman has received many accolades for his excellence in medical teaching, including induction into the Leo M. Davidoff Society in 1993, the American Academy of Neurology award in 2001 and the Montefiore Staff and Alumni Award in 2007.</p>
Manoj Lal Karwa
Cynthia C. Hung
Dr.Hung has a particular interests in strokes, traumatic brain injury, and spasticity management. Dr.Hung did an extra year of training in brain injury medicine to increase my expertise in these topics.
<p>Cynthia C. Hung, MD, is an Attending Physician at Montefiore and is an assistant professor at our Albert Einstein College of Medicine. Since joining the Montefiore team, her clinical focus has been on strokes, traumatic brain injuries, and general rehabilitation management.</p><p>In 2009, Dr. Hung received her Bachelor of Arts in cell biology and neuroscience at Rutgers University. She then attended the University of Medicine and Dentistry of New Jersey, where she received her Doctor of Medicine in 2013. Dr. Hung began her postgraduate training in 2013 as a preliminary medicine resident at Rutgers New Jersey Medical School, completing her residency in 2014. She then became a physical medicine and rehabilitation resident at Icahn School of Medicine at Mount Sinai, which she completed in 2017. Dr. Hung then continued training at NYU Langone Health as a brain injury medicine fellow to increase her expertise in this specialty.</p><p>Extending from her clinical interests, Dr. Hung’s research is also primarily focused on injuries of the brain and stroke. In 2012, she conducted research at Kessler Foundation Research Center on stroke patients with spatial neglect to determine their community mobility. In 2017 she conducted research at NYU- Langone Medical Center on hand and arm rehabilitation after stroke. Her work has been presented nationally.</p><p>Dr. Hung is board certified in Physical Medicine and Rehabilitation and Brain Injury Medicine, and is a member of the American Academy of Physical Medicine and Rehabilitation and the Association of Academic Physiatrists.</p>
Christine Hung
Steven Herskovitz
<p>Dr. Herskovitz is Professor of Clinical Neurology and Director of the EMG Lab / Neuromuscular division. He earned his medical degree from Cornell University Medical Center in 1980. He completed residencies in both Internal Medicine and Neurology, followed by a Fellowship in Electromyography/Neuromuscular Disorders, all at the Albert Einstein College of Medicine. He is a diplomate of the ABIM, ABPN, ABEM, and ABPN-AQNM. His clinical research interests include the peripheral neuropathies, entrapment neuropathies and peripheral neurotoxicology. He has published on various aspects of carpal tunnel syndrome including electrophysiologic diagnosis, treatment and autonomic features, clinical features of a variety of peripheral neuropathies, and the neurotoxicology of pharmaceutical and industrial agents. He is author of: <em>Herskovitz S, Scelsa S, Schaumburg HH. Peripheral Neuropathies in Clinical Practice. Contemporary Neurology Series. Oxford University Press. New York. 2010</em>. Two positions are available yearly in the clinical neurophysiology /EMG fellowship program.</p>
Dr. Herskovitz focuses on the clinical and neurodiagnostic (EMG; neuromuscular ultrasound) evaluation of neuromuscular disorders.
Dr. Herskovitz's research is focused on the clinical and neurodiagnostic assessment of neuropathies.
<p><strong>Bibliography</strong><br /><br /><strong>A. Original Communications in Reviewed Journals:</strong></p>
<p>1. Lipton RB, Krupp L, Horoupian D, Herskovitz S, Arezzo JC, Kurtzberg D. Progressive multifocal leukoencephalopathy of the posterior fossa in an AIDS patient: Clinical, radiographic and evoked potential findings. European Neurology. 28:258?261,1988.</p>
<p>2. Herskovitz S, Lipton RB, Lantos G. NeuroBehcet's disease: CT and clinical correlates. Neurology. 38:1714?1720, 1988.</p>
<p>3. Herskovitz S, Siegel SE, Schneider AT, Nelson SJ, Goodrich JT, Lantos G. Spinal cord toxoplasmosis in AIDS. Neurology. 39:1552?1553, 1989.</p>
<p>4. Loh F, Herskovitz S, Berger AR, Swerdlow M. Brachial plexopathy associated with interleukin 2 therapy. Neurology. 42:462?463, 1992.</p>
<p>5. Newman LC, Herskovitz S, Lipton RB, Solomon S. Chronic paroxysmal headache: Two cases with cerebrovascular disease. Headache 32: 75?76, 1992.</p>
<p>6. Gonzales GR, Herskovitz S, Rosenblum M, et al. Dejerine Roussy syndrome caused by CNS toxoplasmosis in patients with AIDS. Neurology 42: 1107?1109, 1992.</p>
<p>7. Herskovitz S, Gordon M, Strauch B. Shiatsu massage induced injury of the median recurrent motor branch. Muscle & Nerve 15 (10): 1215, 1992.</p>
<p>8. Herskovitz S, Loh F, Berger AR, Kucherov M. Erythromelalgia: Association with hereditary sensory neuropathy and response to amitriptyline. Neurology 43: 621?622, 1993.</p>
<p>9. Herskovitz S, Bieri P, Berger AR. Depressor septi nasi myokymia. Muscle & Nerve 17: 116, 1994.</p>
<p>10. Strominger MB, Slamovits TL, Herskovitz S, Lipton RB. Transient worsening of optic neuropathy as a sequela of the Jarisch?Herxheimer reaction in the treatment of Lyme disease. J Neuro Ophthalmol 14(2): 77?80, 1994.</p>
<p>11. Scelsa SN,, Lipton RB, Sanders H, Herskovitz S. Headache characteristics in hospitalized patients with Lyme disease. Headache 35 (3): 125-130, 1995.</p>
<p>12. Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as chronic sensory demyelinating polyneuropathy. Muscle & Nerve 18: 440-444, 1995.</p>
<p>13. Herskovitz S, Berger AR, Lipton, RB. Low dose, short-term oral prednisone in the treatment of carpal tunnel syndrome. Neurology 45: 1923-1925, 1995.</p>
<p>14. Berger AR, Herskovitz, S, Scelsa SN. Restoration of IVIg efficacy by plasma exchange in CIDP. Neurology 45: 1628-1629, 1995.</p>
<p>15. Oware A, Herskovitz S, Berger AR. Long thoracic nerve palsy associated with chiropractic manipulation. Neurology 18:1351, 1995.</p>
<p>16. Berger AR, Swerdlow M, Herskovitz S. Myasthenia gravis presenting with uncontrollable flatulence and urinary/fecal incontinence. Muscle & Nerve 19: 113-114, 1996.</p>
<p>17. Scelsa SN, Berger AR, Herskovitz S. The diagnostic utility of F waves in L5/S1 radiculopathy. Muscle & Nerve 18: 1496, 1995.</p>
<p>18. Scelsa SN, Herskovitz S, Berger AR. A predominantly motor polyradiculopathy of Lyme disease. Muscle & Nerve 19: 780-783, 1996.</p>
<p>19. Scelsa SN, Herskovitz S, Bieri P, Berger AR. Median mixed and sensory conduction studies in carpal tunnel syndrome. Electroencephalography and Clinical Neurophysiology 109: 268-273, 1998</p>
<p>20. Scelsa SN, Herskovitz S, Reichler B. Treatment of Mononeuropathy Multiplex in Hepatitis C Virus and Cryoglobulinemia. Muscle & Nerve 21: 1526-1529, 1998.</p>
<p>21. Scelsa SN, Herskovitz S. Miller Fisher syndrome: axonal, demyelinating or both? Electromyogr. Clin. Neurophysiol. 40: 497-502, 2000.</p>
<p>22. Manfredi PL, Herskovitz S, Folli F, Pigazzi A, Swerdlow ML. Spinal epidural abscess: treatment options. Eur Neurol 40:58-60, 1998.</p>
<p>23. Berger AR, Schaumburg HH, Freeman K, Gourevitch MN, Herskovitz S, Arezzo JC. Prevalence of peripheral neuropathy in injection drug users. Neurology 1999; 53: 592-597</p>
<p>24. Verghese J, Galanopoulou AS, Herskovitz S. Autonomic dysfunction in idiopathic carpal tunnel syndrome. Muscle & Nerve 23: 1209-1213, 2000.</p>
<p>25. Scelsa S, Berger A, Herskovitz S. Electrophysiologic correlates of L5/S1 radiculopathy. Electromyogr. clin. Neurophysiol 2001, 41, 145-151.</p>
<p>26. Verghese J, Bieri PL, Gellido C, Schaumburg HH, Herskovitz S. Peripheral neuropathy in young-old and old-old patients. Muscle & Nerve 24: 1476-1481, 2001.</p>
<p>27. Scelsa S, Ghali V, Herskovitz S, et al. Blood ãä T cells, Campylobacter jejuni, and GM1 titers in Guillain Barre syndrome. Muscle & Nerve 30: 423-432, 2004.</p>
<p>28. Geyer H, Schaumburg HH, Herskovitz S. Methyl bromide intoxication causes reversible, symmetric, brainstem and cerebellar MRI lesions. Neurology 2005; 64:1279-1281.</p>
<p>29. Herskovitz S, Song H, Cozien D, Scelsa S. Sensory symptoms in acquired neuromyotonia. Neurology 2005;65:1330-1331.</p>
<p>30. Schaumburg HH, Herskovitz S, Cassano V. Occupational manganese neurotoxicity provoked by hepatitis C. Neurology 2006;67:322-3.</p>
<p>31. Blumenthal S, Herskovitz S, Verghese J. Carpal tunnel syndrome in older adults. Muscle & Nerve 2006;34:78-83.</p>
<p>32. Schaumburg HH, Herskovitz S. Is acquired copper deficiency myeloneuropathy from denture cream use a clue to clioquinol-induced subacute myelo-optic neuropathy (SMON)? Neurology 2008; 71 (9):622.</p>
<p>33. Robbins MS, Roth S, Swerdlow ML, Bieri P, Herskovitz S. Optic neuritis and palatal dysarthria as presenting features of post-infectious GQ1b antibody syndrome. Clin Neurol Neurosurg 2009;111:465-466.</p>
<p>34. Issa SS, Herskovitz S, Lipton RB. Acquired neuromyotonia as a paraneoplastic manifestation of ovarian cancer. Neurology 2011;76:101-103 .</p>
<p><strong>B. Books, Chapters in Books, Editorials and Review Articles:</strong></p>
<p>1. Contributing author: Pousada, L, Osborn HH. Emergency Medicine for the House Officer. Williams and Wilkins, 1986. (chapters on headache and CPR).</p>
<p>2. Contributing author: Schaumburg HH, Berger AR, Thomas PK. Disorders of Peripheral Nerves, 2nd edition, F.A. Davis, 1992.</p>
<p>3. Berger AR, Herskovitz S. Cumulative trauma disorders and occupational nerve disease. In: Rosenberg, N ed. Occupational and Environmental Neurology. Butterworth-Heinemann, Boston, 1995.</p>
<p>4. Assistant Editor: Spencer PS, Schaumburg HH, Ludolph AC. Experimental and Clinical Neurotoxicology, 2nd edition. Oxford University Press, 2000.</p>
<p>5. Schaumburg HH, Herskovitz S. The Weak Child – A Cautionary Tale. N Engl J Med 2000 (editorial); 342, 127-129.</p>
<p>6. Herskovitz, S. Toxic neuropathies – Amiodarone, Gold, Perhexilene, Misonidazole. In Medlink Neurology (www.medlink.com), 2001/2002/2003/2004/2005/2006.</p>
<p>7. Herskovitz S, Schaumburg HH. Neuropathy due to drugs. In: Dyck PJ, Thomas PK, editors: Peripheral Neuropathy, 4th edition, 2005.</p>
<p>8. Herskovitz S, Scelsa S, Schaumburg HH. Peripheral Neuropathies in Clinical Practice. Contemporary Neurology Series. Oxford University Press. New York. 2010.</p>
<p>Steven Herskovitz, MD, is Director, Neuromuscular Medicine and Director, Electromyography (EMG) Lab at Montefiore. He is also Professor of Neurology at our Albert Einstein College of Medicine. Dr. Herskovitz’s clinical focus is on the evaluation and management of all neuromuscular disorders, with a particular interest in electrodiagnostic and neuromuscular ultrasound assessment.</p><p>In 1976, Dr. Herskovitz received his Bachelor of Science in biology at the State University of New York at Stony Brook. He then attended Cornell University Medical College, where he received his Doctor of Medicine in 1980. From 1980 to 1987, Dr. Herskovitz completed his postgraduate training at Montefiore. During this time, he spent his first year as a medical intern and next two years as a medical resident. In 1983, he began a three-year neurology residency, becoming Chief Resident in the final year. He ended his postgraduate training with a fellowship in Electromyography and Neuromuscular Diseases.</p><p>Expanding on his clinical focus, Dr. Herskovitz’s research centers on clinical, electrodiagnostic and neuromuscular ultrasound assessment of neuropathies. His work has been published in many peer-reviewed journals, books, review articles and abstracts.</p><p>Dr. Herskovitz is board certified by the American Board of Internal Medicine, the American Board of Psychiatry and Neurology, including Added Qualification in Neuromuscular Medicine, and the American Board of Electrodiagnostic Medicine. He is a member of the American Academy of Neurology and the American Association of Neuromuscular and Electrodiagnostic Medicine.</p>
Betsy Herold
<p><strong>Betsy Herold, M.D.</strong> directs a basic and translational research program, which focuses on virus host interactions. Projects in the lab include studies designed to identify the cellular signaling pathways that herpes simplex viruses (HSV) usurp to promote viral entry and infection. The lab uncovered a previously unappreciated paradigm associated with activation of phospholipid scramblases, which are known to catalyze the movement of phosphatidylserine lipids between the inner and outer leaflet of the plasma membrane. Surprisingly, they found that the exofacial movement of phospholipids is associated with concomitant translocation of intracellular proteins, including the master kinase Akt to the outside, where Akt becomes phosphorylated to activate an “outside-inside” signaling cascade that promotes viral entry. This pathway is also usurped by SARS-CoV-2 and is important for cellular processes including apoptosis. In collaboration with the Almo lab, they have engineered cell impermeable kinase inhibitors. These compounds block viral entry and prevent induction of apoptosis by select TNF ligands.</p>
<p> Serendipitously, in studying this signaling pathway, the lab identified a novel candidate vaccine for the prevention and treatment of HSV infections. Most efforts to develop a vaccine have focused on neutralizing antibodies that target HSV glycoprotein D (gD), but all of these have failed in clinical trials. Instead, the lab (in collaboration with the Jacobs lab), engineered a virus completely deleted in gD. Glycoprotein D is required for viral entry and cell-to-cell spread, thus the deletion virus (DgD-2) is restricted a single cycle and will not spread. This candidate vaccine elicits T cell responses and high titer, polyfunctional antibodies that protect through antibody-dependent cell mediated cytotoxicity (ADCC). The vaccine prevents the establishment of latency in mice and is significantly more protective in multiple small animal models than prior vaccines that have failed in clinical trials. The lab has subsequently isolated monoclonal antibodies (mAbs) that have this protective ADCC activity and both the vaccine and the mAbs are being advanced for preclinical development. Studies to understand why this vaccine elicits ADCC-mediating antibodies whereas gD vaccines and primary HSV infection only elicit neutralizing antibodies led to the identification of a key role for TNFRSF14 (aka HVEM) in generating and mediating ADCC responses. HVEM is an immune cell surface protein that functions in signal transduction pathways that regulate inflammatory or inhibitory immune responses but its role in shaping the B cell repertoire and in providing a second signal for ADCC had not been previously described and has implications for vaccine development and oncolytic therapies. </p>
<p> The third major area of basic research involves defining the molecular mechanisms underlying the HIV-HSV syndemic. Epidemiological studies have consistently demonstrated that being HSV seropositive is associated with an increased risk for HIV acquisition, replication, higher plasma viral loads and more frequent episodes of HIV reactivation. Using primary cells from patients and HIV latently infected cell lines, the lab has identified several mechanisms by which HSV promotes HIV latency reversal and replication including upregulation of the noncoding RNA, <em>Malat1</em>, and downregulation of IL-32. Defining these pathways may lead to identification of new strategies to “shock and kill” or “block and lock” HIV.</p>
<p> Clinical studies include prevention of infectious disease complications in transplantation. Members of the research group are involved in studies to optimize pre-emptive prophylaxis for CMV and EBV, vaccine responses in transplantation recipients, and others</p><p>Studies with vaginal microbicides have resulted in the expnasion of studies to focus on soluble mucosal immunity in the genital tract. We found that .female genital tract secretions collected from healthy women provide variable, but significant protection against both HSV and HIV. Mechanistic studies suggest that this endogenous activity is mediated by defensins and other antimicrobial peptides. This endogenous activity may serve as a biomarker of a "healthy mucosal immune environment" and thus provide a surrogate marker to evaluate the safety of vaginal microbicides. In addition, identification of the mediators that contribute to this endogenous activity could lead to development of new strategies to boost this host defense and help protect against infection. These studies are being conducted in collaboration with the proteomics core facility at AECOM. Additionally, we are testing the hypothesis that HSV triggers changes in the mucosal environment, which allow it to escape cervical secretion defenses, enhance its own infectivity and facilitate HIV co-infection. Our preliminary observations support the paradigm that HSV disrupts the epithelial barrier by targeting tight junction and adherens junction proteins, and interferes with host defenses by triggering an inflammatory response and a loss in protective proteins such as SLPI. These changes could facilitate both its own infectivity and enhance HIV co-infection.<br /><br /></p>
<p>Results obtained from this bench research are critical to the laboratory's translational studies. The focus of the Translational Microbicide Research Program is to identify optimal combinations of topical microbicides that are safe and target different steps in HIV life cycle, thus reducing the risks of drug resistance and providing greater protection than could be achieved with a single agent, and also target HSV infection. Candidate combinations are evaluated using a multi-tiered approach for anti-viral activity and safety using human cervical cultures, as well as primary T cells and macrophages, in the presence of cervicovaginal secretions and seminal plasma. Leading combinations are then evaluated in human explant cultures (cervical, vaginal) and in murine genital models and a new cotton rat model for anti-viral activity and for the impact on mucosal immunity. If results of these pre-clinical studies suggest that candidate microbicides are safe and effective, the drugs are advanced for regulatory testing, and undergo evaluation in Phase I clinical studies.<br /><br /></p>
<p>Clinical research interests also include prevention of infectious disease complications in transplantation. Members of the research group are involved in studies to optimize pre-emptive prophylaxis for CMV and EBV, vaccine responses in transplantation recipients, and other related infectious complications.<br /><br /></p>
<div>Dr. Herold directs a translational research program focused on the interactions between viruses and their host and using that knowledge to develop novel treatment and prevention strategies. Through her basic science studies, Dr. Herold has developed a unique candidate vaccine to prevent herpes simplex virus (HSV) infections, which is being advanced for phase I clinical trials. Studies of this vaccine uncovered a previously unappreciated immune evasion strategy; this knowledge may accelerate the development of drugs to bolster vaccine and monoclonal antibody efficacy against a range of pathogens. </div>
<div><span style="white-space: pre;"> </span> </div>
<div>Her studies on HIV focus on the development of safe and effective pre-exposure prophylactic strategies and on investigating how HSV interacts with HIV to reactivate HIV. Dr. Herold's team also has discovered a previously unrecognized phenomenon in cell biology in which HSV and other viruses activate a mechanism that helps them gain entry and infect healthy cells. This provides a novel target for the development of new antiviral drugs. <br /><br /></div>
<div>Most recently, her lab has studied why children respond differently and are relatively protected from severe COVID-19. Defining the differences in the immune response in children compared to adults will provide insights into protective immunity against this virus and future pandemic viruses. <br /><br /></div>
<div>Her clinical research focuses on infections in pediatric transplant recipients. Dr. Herold helped established and is co-chair of the Pediatric Infectious Diseases Society Transplant Research Network (PIDTRAN), which supports and promotes projects to prevent and treat infectious diseases among child transplant recipients. Dr. Herold has served on the Office of AIDS Research Advisory Council and on the Pediatric Infectious Diseases Society Council. She has been continuously funded by the NIH since 1989. Dr. Herold has over 180 publications in peer-reviewed journals and has presented her work internationally.</div>
Pediatric Infectious Diseases.
Prevention and treatment of infections in solid and stem cell transplant patients and other immunocompromised patients.
<p>Betsy Herold, MD, is Chief of the Division of Pediatric Infectious Diseases and Vice Chair for Research at Children's Hospital at Montefiore. Dr. Herold is also a Professor of Pediatrics, Microbiology & Immunology, and Obstetrics & Gynecology and Women's Health at our Albert Einstein College of Medicine. She specializes in pediatric infectious diseases. </p><p>Dr. Herold received her Bachelor of Arts in Biology in 1978 from Brown University and went on to receive her Doctor of Medicine from the University of Pennsylvania Medical School in 1982. Dr. Herold completed an internship and residency in pediatrics at Children's Memorial Hospital, where she became a Chief Resident in 1985. She then began a fellowship in research at Hagedorn Research Laboratory in Gentofte, Denmark. In 1987, Dr. Herold began a fellowship in pediatric infectious diseases at Children's Memorial Hospital, followed by a Research Associate/Postdoctoral Virology Fellowship in the Department of Microbiology and Immunology at Northwestern University in Chicago. </p><p>Dr. Herold's clinical research focuses on the prevention and treatment of infections in solid and stem cell transplant patients and other immunocompromised patients. Dr. Herold has also been involved in research in Kawasaki disease and the emergence of methicillin-resistant staphylococcus aureus (MRSA) in the community. Dr. Herold directs a basic and translational research program on the prevention of herpes simplex virus (HSV) and HIV infections through the development of vaccines and novel antivirals. The current major focus of her lab is on a novel, paradigm-shifting, single-cycle vaccine to prevent HSV-1 and HSV-2. She has been continuously funded by the NIH since 1989. Dr. Herold has over 150 peer reviewed publications in peer-reviewed journals and has presented her work internationally. </p><p>In 2012, Dr. Herold received the Clinical Science Faculty Mentor Award from the Albert Einstein College of Medicine. She has also been awarded the Henry and Jacob Lowenberg Prize in Pediatrics and the Pediatric Infectious Disease Young Investigator Award. Dr. Herold is board certified by the American Board of Pediatrics in Pediatrics and in Pediatric Infectious Diseases. </p>
Sheryl R. Haut
<p>Dr. Sheryl Haut is Director of the Adult Epilepsy Program and Chief of Service, Neurology at Montefiore Einstein. She is the previous Chair of the North American Commission of the International League Against Epilepsy. Her research interests include: the temporal distribution of seizures, with emphasis on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy. She is currently conducting electronic diary studies of seizure prediction and was the Principal Investigator of the first randomized controlled trial of stress management for refractory epilepsy using smartphone diaries. Dr. Haut has a Masters in Clinical Research Methods, and completed a K23 career development award from the NIH. She maintains an active adult epilepsy practice at Montefiore Medical Center, Moses Division.</p>
Dr. Haut focuses on the special needs of epilepsy patients, such as pregnancy, stress, driving, work-related issues and issues in the elderly.
Dr. Haut's research is focused on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy.
<ol>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><!-- [if !supportLists]--><span style="mso-bidi-font-size: 12.0pt; border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in;">Correa DJ, Labovitz DL, Milstein MJ, Monderer R, Haut SR. <strong><span style="font-weight: normal; mso-bidi-font-weight: bold;">Folding a neuroscience </span></strong></span><strong style="text-indent: -0.25in;"><span style="font-weight: normal; mso-bidi-font-weight: bold;">center into streamlined Covid-19 response teams: Lessons in origami. Neurology 2020, in press.</span></strong></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span lang="EN" style="text-indent: -0.25in;"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><span class="author" style="text-indent: -0.25in;"><span lang="EN">Galanopoulou, AS</span></span><span lang="EN" style="text-indent: -0.25in;">, <span class="author">Ferastraoaru, V</span>, <span class="author">Correa, DJ</span>, </span><span lang="EN" style="text-indent: -0.25in;">Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler M, Ballaban-Gil K, Haut SR, Moshé SL, Boro A. </span><span lang="EN" style="text-indent: -0.25in;"> <span class="articletitle">EEG findings in acutely ill patients investigated for SARS</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN" style="mso-bidi-font-size: 12.0pt; font-family: 'Cambria Math','serif'; mso-bidi-font-family: 'Cambria Math'; mso-ansi-language: EN;">‐</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN">CoV-2/COVID</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN" style="mso-bidi-font-size: 12.0pt; font-family: 'Cambria Math','serif'; mso-bidi-font-family: 'Cambria Math'; mso-ansi-language: EN;">‐</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN">19: A small case series preliminary report</span></span><span lang="EN" style="text-indent: -0.25in;">. Epilepsia Open. <span class="pubyear">2020</span>; <span class="vol">5</span>: <span class="pagefirst">314</span>– <span class="pagelast">324</span>. </span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><a href="https://www.sciencedirect.com/science/article/pii/S0920121119303869#!">… class="text2"><span style="color: windowtext; text-decoration-line: none;">Chiang S, </span></span></a><a name="baut0015"></a>Haut SR. <a name="baut0020"></a>Ferastaoaru V, <a name="baut0025"></a>Rao VR, <a name="baut0030"></a> M, <a name="baut0035"></a>Theodore WH, <a href="https://www.sciencedirect.com/science/article/pii/S0920121119303869#!">… class="text2"><span style="color: windowtext; text-decoration-line: none;">Moss</span></span></a><a name="baut0040"></a> R, Goldenholz DM. <span class="title-text">Individualizing the definition of seizure clusters based on temporal clustering analysis. Epilepsy Res 2020;163:1-10.</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><strong style="text-indent: -0.25in;"><span style="font-weight: normal;"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span></strong><strong style="text-indent: -0.25in;"><span style="border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in; font-weight: normal; mso-bidi-font-weight: bold;">Privitera M, Haut SR, Lipton RB, McGinley J, Cornes S. Seizure Self-prediction in a Randomized Controlled Trial of Stress Management. Neurology 2019;93(22):e2021-e2031</span></strong><span style="text-indent: -0.25in; color: windowtext;">1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span lang="EN" style="text-indent: -0.25in; color: windowtext;">Ferastraoaru V, Goldenholz DM, Chiang S, Moss R, Theodore WH, Haut SR. Characteristics of large patient-reported outcomes: Where can one million seizures get us? Epilepsia Open. 2018 Jul 4;3(3):364-373 </span></p>
</li>
<li>
<p class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> </p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span style="text-indent: -0.25in; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span><span lang="EN" style="text-indent: -0.25in;">Goldenholz DM, Goldenholz SR, Moss R, French J, Lowenstein D, Kuzniecky R, Haut S, Cristofaro S, Detyniecki K, Hixson J, Karoly P, Cook M, Strashny A, Theodore WH. Is seizure frequency variance a predictable quantity? Ann Clin Transl Neurol. 2018 Jan 9;5(2):201-207</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span style="text-indent: -0.25in; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span><span style="text-indent: -0.25in;">Haut SR, Lipton RB, Cornes S, Dwivedi AK, Wasson R, Cotton S, Strawn J, Privitera M. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial. </span><span class="jrnl" style="text-indent: -0.25in;">Neurology</span><span style="text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">. 2018 Mar 13;90(11)</span></p>
<p style="margin-left: .25in; text-indent: -.25in; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in;"> </p>
<p class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"> </p>
</li>
<li>Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshe SL, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian E, Zuberi SM. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017 Apr;58(4):531-542</li>
<li>Patel P, Ferastaoaru V, Gold D, Lipnick A, Jehle R, Haut SR. Clinical characterization of the pre-ictal state in the pediatric population: A caretaker’s perspective. Epilepsy Behav. 2017 Apr 18;70(Pt A):193-197</li>
<li>Robbins MS, Haut SR, Lipton RB, Milstein MJ, Ocava LC, Ballaban-Gil K, Moshé SL, Mehler MF. A dedicated scholarly research program in an adult and pediatric neurology residency program. Neurology. 2017 Apr 4;88(14):1366-1370</li>
<li>Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in Seizure emergencies: A systematic review. Epilepsy Behav. 2016 Oct;63:109-117.</li>
<li>Ferastraoaru V, Schulze-Bonhage A, Lipton RB, Dümpelmann M, Legatt AD, Blumberg J, Haut SR. Termination of seizure clusters is related to the duration of focal seizures. Epilepsia 2016 Mar 31.</li>
<li>Pillai J, Haut SR, Masur D. Orbitofrontal cortex dysfunction in Psychogenic Non-Epileptic Seizures. A proposal for a two-factor model. Med Hypotheses. 2015 Apr;84(4):363-9</li>
<li>Haut SR. Seizure Clusters: Characteristics and Treatment. Curr Opin Neurol. 2015 Apr;28(2):143-50</li>
<li>Lipton RB,BuseDC, Hall CB, Tennen H, DeFreitas TA, Borkowski TM, Haut SR. Reduction in Perceived Stress as a Migraine Trigger: Testing the “Let-down Headache” Hypothesis. Neurology 2014; Apr 22;82(16):1395-401</li>
<li>Privitera M, Walters M, Lee I, Polak E, Fleck A, Schwieterman D, Haut SR. Characteristics of People with Stress Precipitated Seizures. Epilepsy Behav 2014 Oct;41:74-77</li>
<li>Haut SR, Hall CB, Borkowski T, Tennen H, Lipton RB. Modeling seizure self-prediction: An e-diary study. Epilepsia 2013; Nov;54(11):1960-7.</li>
<li>Haut SR. Predicting seizures: Are we there yet? Epilepsy Currents 2013 Nov;13(6):276-8.</li>
<li>Haut SR, Hall CB, Borkowski T, Tennen H, Lipton RB. Clinical features of the pre-ictal state: Mood changes and premonitory symptoms. Epilepsy and Behavior 2012, 23:415-421.</li>
<li>Pillai J, Haut SR. Patients with epilepsy and psychogenic non-epileptic seizures: An inpatient video-EEG monitoring study. Seizure. 2012, 21(1):24-7.</li>
<li>Schulze-BonhageA, Haut SR. Premonitory features and seizure self-prediction: Artifact or real? Epilepsy Res 2011, 97(3);231-235.</li>
<li>Haut SR, Lipton RBL. Predicting Seizures: A Behavioral Approach. Neurol Clinics 2009, 27(4);925-940.</li>
<li>Haut SR. Psychiatric History and Temporal Lobectomy Outcome: Looking to the Past to Predict the Future. Epilepsy Currents 2009, 9(5):1-3</li>
<li>Haut SR, Katz M, Masur J, Lipton RBL. Seizures in the Elderly: Impact on Mental Status, Mood and Sleep. Epilepsy and Behavior 2009;14(3):540-544.</li>
<li>Hall CB, Lipton RB, Tennen H, Haut SR. Early Follow-up Data From Seizure Diaries Can Be Used To Predict Subsequent Seizures in Same Cohort By Borrowing Strength Across Participants. Epilepsy and Behavior 2009;14(3);472-475.</li>
<li>Bower CM, Hays RD, Devinsky O, Spencer SS, Sperling MR, Haut S, Vassar S, Vickrey BG. Expectations Prior to Epilepsy Surgery: An Exploratory Comparison of Men and Women. Seizure 2009;18(3):228-231</li>
<li>Brody BD and Haut SR. Ending the Doctor-Patient Relationship in Neurology Practice. The Neurologist 2009;15(5): 277-81.</li>
<li>Haut SR, Hall CD, Masur J, Lipton RB. Seizure Occurrence: Precipitants and Prediction. Neurology 2007;69 1905-1910.</li>
<li>Lado F, Spiegel R, Masur J, Boro A, Haut SR. Value of routine screening for bone demineralization in an urban population of patients with epilepsy. Epil Res 2007; 78(2-3);155-160</li>
<li>Chin PS, Berg AT, Spencer SS, Sperling MR, Haut S et al. Employment Outcomes Following Resective Epilepsy Surgery. Epilepsia 2007;Dec;48(12):2253-7.8.<span style="font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-size: 7.0pt; line-height: normal; font-variant: normal;"> </span></li>
<li>Haut SR, Hall CD, LeValley A, Lipton RB. Can patients with epilepsy predict their seizures? Neurology, 2007; 68:262-266.</li>
<li>Spencer SS, Berg AT, Vickrey BG, Sperling MR, Bazil CW, Haut S, Langfitt JT, Walczak TS, Devinsky O; Multicenter Study of Epilepsy Surgery. Health-related quality of life over time since resective epilepsy surgery. Ann Neurol. 2007 Oct;62(4):327-34</li>
<li>Haut SR, Bigal M, Lipton RB. Chronic Disorders With Episodic Manifestations: Focus on Epilepsy and Migraine. Lancet Neurology 2006;5:148-157. </li>
</ol>
<p>Dr. Sheryl Haut is Director of the Adult Epilepsy Program at Montefiore. She has extensive experience treating all forms of epilepsy in young and older adults, and in tailoring treatments to the individual. She focuses on special needs such as pregnancy, stress, driving, work related issues, and issues in the elderly.</p> <p>Dr. Haut has an extensive research background, including a Masters of Clinical Research with Distinction from Albert Einstein College of Medicine. Her research interests focus on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy. She is one of the first investigators to run a clinical trial of stress management for epilepsy, using smartphone diaries.</p> <p>Dr. Haut is the current Chair of the North American Commission of the International League Against Epilepsy, and is active nationally in the American Epilepsy Society, and the American Academy of Neurology, serving on committees of both organizations. She has authored more than 50 papers/book chapters on epilepsy, and has been featured in Top Doctors of NY annually since 2009. She maintains an active adult epilepsy practice at the Moses Campus.</p>
Samuel V. Gorstein
<p>Samuel Gorstein, MD, is Director, Resident Education, Pediatric Intensive Care Unit (PICU) at the Children’s Hospital at Montefiore Einstein (CHAM) and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Dr. Gorstein’s clinical focus is on the care of critically ill infants, children and adolescents, focusing on conditions requiring intensive monitoring, life support and complex interventions, such as respiratory failure, sepsis, trauma and post-surgical recovery.
</p><p>After obtaining a Bachelor of Science in Biophysics from Brown University, Dr. Gorstein attended the University of Massachusetts Medical School, where he received his Doctor of Medicine in 2009. He then began his postgraduate training with an internship and residency in Pediatrics at Baystate Medical Center from 2009 to 2012. In 2015, he completed a fellowship in Pediatric Critical Care at Massachusetts General Hospital. </p><p>Dr. Gorstein oversees resident education in the PICU and has developed a didactic curriculum for residents rotating through the PICU at CHAM. His research aligns with his clinical expertise, and his work has been shared through peer-reviewed publications, invited presentations, abstracts, and poster presentations at professional meetings. </p><p>Dr. Gorstein is board-certified in Pediatrics and Pediatric Critical Care Medicine. He is a member of the American Academy of Pediatrics and the Society of Critical Care Medicine.
</p>
Charles C. Esenwa
<p>Charles Esenwa is an Assistant Professor of Neurology at Albert Einstein College of Medicine and clinical stroke neurologist at Montefiore Medical Center. Dr. Esenwa attended medical school at SUNY Downstate College of Medicine, and completed a residency in Neurology at the Neurological Institute of New York, where he also served as chief resident and a fellow in vascular neurology. While at Columbia, he completed formal training in neuroepidemiology under an NIH T32 grant.<br />He is dedicated to humanistic patient care and is the recipient of the Arnold P. Gold Humanism in Medicine Award, and the Neurological Institute’s Daniel Sciarra patient care and humanism award. He has published on acute stroke management, stroke risk factors, secondary stroke prevention and stroke disparities, and is interested in advancing health care delivery to populations on the local, national and international levels.</p>
Dr. Esenwa specializes in acute stroke care and stroke prevention in high-risk communities. He is the medical director of the Montefiore Comprehensive Center for Stroke Care.
<p class="MsoListParagraph" style="mso-add-space: auto; line-height: normal; mso-outline-level: 1; background: white; margin: 12.0pt 0in 6.0pt 0in;"><span style="font-family: 'Verdana',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Arial; color: black; mso-color-alt: windowtext; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">Journal Publications</span></p>
<p class="desc" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Esenwa C</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">, Cheng NT, Lipsitz E, Hsu K, Zampolin R, Gersten A, Antoniello D, Soetanto A, Kirchoff K, Liberman A, Mabie P, Nisar T, Rahimian D, Brook A, Lee SK, Haranhalli N, Altschul D, Labovitz D. <em>COVID-19-Associated Carotid Atherothrombosis and Stroke.</em> AJNR Am J Neuroradiol. 2020 Aug 20. doi: 10.3174/ajnr.A6752.</span></p>
<p class="desc" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Esenwa C,</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;"> Parides MK, Labovitz DL. <em>The effect of COVID-19 on stroke hospitalizations in New York City</em>. J Stroke Cerebrovasc Dis. 2020 Oct;29(10):105114. doi: 10.1016/j.jstrokecerebrovasdis.2020.105114. Epub 2020 Jul 13.</span></p>
<p class="desc" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Altschul DJ, <strong>Esenwa C</strong>, Haranhalli N, Unda SR, de La Garza Ramos R, Dardick J, Fernandez-Torres J, Toma A, Labovitz D, Cheng N, Lee SK, Brook A, Zampolin R. <em>Predictors of mortality for patients with COVID-19 and large vessel occlusion</em>. Interv Neuroradiol. 2020 Oct;26(5):623-628. doi: 10.1177/1591019920954603. Epub 2020 Aug 30. PMID: 32862753.</span></p>
<p class="desc" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Liberman AL, Wang C, Friedman BW, Prabhakaran S, <strong>Esenwa CC</strong>, Rostanski SK, Cheng NT, Erdfarb A, Labovitz DL, Lipton RB. <em>Head Computed tomography during emergency department treat-and-release visit for headache is associated with increased risk of subsequent cerebrovascular disease hospitalization</em>. Diagnosis (Berl). 2020 Oct 5:/j/dx.ahead-of-print/dx-2020-0082/dx-2020-0082.xml. </span></p>
<p class="desc" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">McHugh DC<strong>, Esenwa C</strong>. A Novel COL4A2 <em>Mutation Associated with Recurrent Strokes</em>. J Stroke Cerebrovasc Dis. 2020 Oct;29(10):105156. doi:</span></p>
<p class="desc" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Altschul DJ, Haranhalli N, <strong>Esenwa C</strong>, Unda SR, de La Garza Ramos R, Dardick J, Fernandez-Torres J, Toma A, Labovitz D, Cheng N, Lee SK, Brook A, Zampolin R. <em>The Impact of COVID-19 on Emergent Large-Vessel Occlusion: Delayed Presentation Confirmed by ASPECTS.</em> AJNR Am J Neuroradiol. 2020 Sep 3. doi: 10.3174/ajnr.A6800.</span></p>
<p class="desc" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Liberman AL, Navi BB, <strong>Esenwa</strong> CC, Zhang C, Song J, Cheng NT, Labovitz DL, Kamel H, Merkler AE. <em>Misdiagnosis of Cervicocephalic Artery Dissection in the Emergency Department.</em></span></p>
<p class="details" style="margin: 0in 0in 0in .5in;"><span class="jrnl"><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Stroke</span></span><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">. 2020 Apr 16:STROKEAHA120029390. doi: 10.1161/STROKEAHA.</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Esenwa</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;">, C. et al<em>. Racial Differences in Mechanical Thrombectomy Utilization for Ischemic Stroke in the United States</em>. Ethn Dis 30, 91-96 (2020).</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;">Liberman, A. L., Bakradze, E., McHugh, D. C., </span><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Esenwa, </span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;">C. C. & Lipton, R. B. <em>Assessing diagnostic error in cerebral venous thrombosis via detailed chart review.</em> Diagnosis (Berl) 6 (2019).</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Esenwa,</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;"> C., Labovitz, D. & Caplan, L. R. "Basilar Web" Causing Basilar Branch Infarction. J Stroke Cerebrovasc Dis 28, 104366 (2019).</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;">Dardick, </span><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Esenwa, C</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;">., et al. <em>Acute Lateral Medullary Infarct due to Giant Cell Arteritis: A Case Study</em>. Stroke 50, e290-e293 (2019).</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;">Bakradze E, Kirchoff KF, Antoniello D, Springer MV, Mabie PC, </span><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black;">Esenwa CC,</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;"> Labovitz DL, Liberman AL.<em>Varicella Zoster Virus Vasculitis and Adult Cerebrovascular Disease</em>. Neurohospitalist 9, 203-208 (2019).</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial;">Esenwa, C</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial;">., Tshiswaka, DL., Gebregziabher, M., Ovbiagele, B. <em style="mso-bidi-font-style: normal;"><span style="mso-bidi-font-weight: bold;">Historical Slavery and Modern-Day Stroke Mortality in the United States Stroke Belt</span></em><span style="mso-bidi-font-weight: bold;">.<em> Stroke</em>. 2018 (in press)</span></span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">Boehme, A., <strong>Esenwa</strong>, C., Elkind, M.S. </span><em style="mso-bidi-font-style: normal;"><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;">Stroke Risk Factors, Genetics, and Prevention.</span></em><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-bidi-font-weight: bold;"> Circulation Research. 120, 3 (2017)</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt;">Esenwa</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, C.C. & Elkind, M.S. <em style="mso-bidi-font-style: normal;">Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke</em>. Nat Rev Neurol 12, 594-604 (2016).</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt;">Esenwa</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, C. & Gutierrez, J. <em style="mso-bidi-font-style: normal;">Secondary stroke prevention: challenges and solutions</em>. Vasc Health Risk Manag 11, 437-50 (2015).</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt;">Esenwa</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, C.C. & Elkind, M.S<em style="mso-bidi-font-style: normal;">. A questionable cause of intracerebral hemorrhage.</em> JAMA Neurol 70, 653-4 (2013).</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial;">Kummer B, Kerner B,<strong style="mso-bidi-font-weight: normal;"> Esenwa C. </strong><em style="mso-bidi-font-style: normal;">Voltage Gated Potassium Channel Antibody Encephalitis Associated with Hyperglycemia</em>. J Clin Case Rep. 2014 Dec. 4:464</span></p>
<p class="details" style="text-indent: -.25in; mso-list: l1 level1 lfo2; margin: 0in 0in 0in .5in;"><!-- [if !supportLists]--><span style="font-size: 11.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: black;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt;">Esenwa</span></strong><span style="font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, C.C. & Leaf, D.E. <em style="mso-bidi-font-style: normal;">Colpocephaly in adults.</em> BMJ Case Rep 2013 (2013).</span></p>
<p class="MsoNormal"> </p>
<p class="MsoNormal"><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial;">Book Publications </span></p>
<ul style="margin-top: 0in;" type="disc">
<li class="MsoNormal" style="mso-list: l0 level1 lfo1; text-autospace: ideograph-numeric ideograph-other;"><strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt;">Esenwa C</span></strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, Czeisler B, Mayer S. 2015<em style="mso-bidi-font-style: normal;">. Chapter 35</em>, <em style="mso-bidi-font-style: normal;">Acute Ischemic Stroke</em>.</span><span lang="EN" style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-ansi-language: EN;"> In E. Louis, S. Mayer and L. Rowland</span><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, Merritt’s Neurology Thirteenth Ed. Philadelphia, PA: Walters Kluwer.</span></li>
<li class="MsoNormal" style="mso-list: l0 level1 lfo1; text-autospace: ideograph-numeric ideograph-other;"><strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt;">Esenwa C</span></strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, Elkind M. 2015. <em style="mso-bidi-font-style: normal;">Chapter 44, </em></span><em style="mso-bidi-font-style: normal;"><span lang="EN" style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-ansi-language: EN;">Primary and Secondary Stroke Prevention</span></em><span lang="EN" style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-ansi-language: EN;">. In E. Louis, S. Mayer and L. Rowland</span><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, Merritt’s Neurology Thirteenth Ed. Philadelphia, PA: Walters Kluwer.</span></li>
<li class="MsoNormal" style="mso-list: l0 level1 lfo1; text-autospace: ideograph-numeric ideograph-other;"><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">Rinaldi A, <strong>Esenwa C.</strong> 2015. <em style="mso-bidi-font-style: normal;">Chapter 121, Gastric and Genitourinary Function and the Brain</em></span><span lang="EN" style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-ansi-language: EN;">.<span style="mso-spacerun: yes;"> </span>In E. Louis, S. Mayer and L. Rowland</span><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">, Merritt’s Neurology Thirteenth Ed. Philadelphia, PA: Walters Kluwer.</span></li>
</ul>
<p class="MsoNormal" style="margin-bottom: 6.0pt; mso-outline-level: 1; background: white;"> </p>
<p class="MsoNormal" style="margin-bottom: 6.0pt; mso-outline-level: 1; background: white;"><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif; mso-bidi-font-family: Arial; color: black; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;">Abstracts:</span></p>
<ul type="disc">
<li class="MsoNormal" style="color: black; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: 13.65pt; mso-list: l2 level1 lfo3; tab-stops: list .5in; text-autospace: ideograph-numeric ideograph-other;"><strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif;">Esenwa et al</span></strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif;">. <em>Identifying acute ischemic stroke by analyzing ICD-10 claims data using machine learning models. International Stroke Conference 2017 meeting.</em></span></li>
<li class="MsoNormal" style="color: black; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: 13.65pt; mso-list: l2 level1 lfo3; tab-stops: list .5in; text-autospace: ideograph-numeric ideograph-other;"><strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif;">Esenwa et al</span></strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif;">. <em>Identifying stroke subtypes with high accuracy using machine learning and ICD-9 claims data</em>. International Stroke Conference 2017 meeting.</span></li>
<li class="MsoNormal" style="color: black; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: 13.65pt; mso-list: l2 level1 lfo3; tab-stops: list .5in; text-autospace: ideograph-numeric ideograph-other;"><strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif;">Esenwa et al</span></strong><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif;">. <em>T1 Rho Magnetic Resonance (MR) imaging can quantify acute cerebrovascular infarct in humans and is stable in the subacute period. </em>International Stroke Conference 2017 meeting.</span></li>
<li class="MsoNormal" style="color: black; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: 13.65pt; mso-list: l2 level1 lfo3; tab-stops: list .5in; text-autospace: ideograph-numeric ideograph-other;"><span style="mso-bidi-font-size: 11.0pt; font-family: 'Verdana',sans-serif;">Soun J & <strong>Esenwa </strong>C. Quantitative T1 Rho MR imaging of Acute Ischemic Infarct. ASNR meeting April, 2016 Poster</span></li>
</ul>
<p>Charles C. Esenwa, MD, MS, is a Director at Montefiore’s Center for Comprehensive Stroke Care and Assistant Professor at our Albert Einstein College of Medicine. He specializes in vascular neurology, with a particular interest in acute stroke management and stroke prevention strategies in high-risk individuals.</p><p>After receiving his Bachelor of Science in microbiology from Penn State University in 2006, Dr. Esenwa attended SUNY Downstate Medical Center, earning his medical degree in 2010. He pursued his postdoctoral training at NewYork-Presbyterian Hospital, completing a medical internship in 2011 and a residency in the department of neurology in 2014. He was invited to complete an additional year, serving as chief resident for the department of neurology. From 2015 to 2017, he continued at the institution as a vascular neurology clinical and neuroepidemiology postdoctoral fellow. In 2017, he earned his Master of Science in neuroepidemiology from Columbia University Mailman School of Public Health.</p><p>Dr. Esenwa’s research focus is on acute stroke management, stroke risk factors and stroke prevention. His research has been published in several reviewed journals, books and abstracts.</p><p>Dr. Esenwa is the recipient of the 2010 Leonard Tow Humanism in Medicine Award from the Arnold P. Gold Foundation and the 2014 Columbia University Department of Neurology Daniel Sciarra Award for patient care and humanism. He was selected to participate in the American Academy of Neurology’s Emerging Leaders Program in 2018-2019. Dr. Esenwa is an active board member of the New York State Neurological Society, and he is a member of the American Heart Association and the American Academy of Neurology.</p>